DOCSLIB.ORG

Anorectal Disorders Satish S

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Anorectal Disorders Satish S Gastroenterology 2016;150:1430–1442 Anorectal Disorders Satish S. C. Rao,1 Adil E. Bharucha,2 Giuseppe Chiarioni,3,4 Richelle Felt-Bersma,5 Charles Knowles,6 Allison Malcolm,7 and Arnold Wald8 1Division of Gastroenterology and Hepatology, Augusta University, Augusta, Georgia; 2Department of Gastroenterology and Hepatology, Mayo College of Medicine, Rochester, Minnesota; 3Division of Gastroenterology of the University of Verona, Azienda Ospedaliera Universitaria Integrata di Verona, Verona, Italy; 4Division of Gastroenterology and Hepatology and UNC Center for Functional GI and Motility Disorders, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina; 5Department of Gastroenterology/Hepatology, VU Medical Center, Amsterdam, The Netherlands; 6National Centre for Bowel Research and Surgical Innovation, Blizard Institute, Queen Mary University of London, London, United Kingdom; 7Division of Gastroenterology, Royal North Shore Hospital, and University of Sydney, Sydney, Australia; 8Division of Gastroenterology, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin This report defines criteria and reviews the epidemiology, questionnaires and bowel diaries are correlated,5 some pathophysiology, and management of the following com- patients may not accurately recall bowel symptoms6; hence, mon anorectal disorders: fecal incontinence (FI), func- symptom diaries may be more reliable. tional anorectal pain, and functional defecation disorders. In this report, we examine the prevalence and patho- FI is defined as the recurrent uncontrolled passage of fecal physiology of anorectal disorders, listed in Table 1,and material for at least 3 months. The clinical features of FI provide recommendations for diagnostic evaluation and are useful for guiding diagnostic testing and therapy. management. These supplement practice guidelines rec- ANORECTAL Anorectal manometry and imaging are useful for evalu- ommended by the American Gastroenterological Associa- fl ating anal and pelvic oor structure and function. Educa- tion7 and American College of Gastroenterology.8 We will tion, antidiarrheals, and biofeedback therapy are the not address anorectal symptoms secondary to a neurologic mainstay of management; surgery may be useful in re- or systemic disorder. The revised diagnostic criteria fractory cases. Functional anorectal pain syndromes are include a minimum duration of symptoms that were defined by clinical features and categorized into 3 sub- selected arbitrarily to avoid the inclusion of self-limited types. In proctalgia fugax, the pain is typically fleeting and conditions. lasts for seconds to minutes. In levator ani syndrome and unspecified anorectal pain, the pain lasts more than 30 minutes, but in levator ani syndrome there is puborectalis F1. Fecal Incontinence fi tenderness. Functional defecation disorders are de ned by Definition ‡2 symptoms of chronic constipation or irritable bowel Fecal incontinence (FI) is defined as the recurrent un- syndrome with constipation, and with ‡2 features of controlled passage of fecal material for at least 3 months. impaired evacuation, that is, abnormal evacuation pattern fl on manometry, abnormal balloon expulsion test, or We recognize that fecal staining of underwear may re ect impaired rectal evacuation by imaging. It includes 2 sub- poor hygiene, prolapsing hemorrhoids, or rectal prolapse types: dyssynergic defecation and inadequate defecatory rather than true FI, but for practical purposes it is included fi propulsion. Pelvic floor biofeedback therapy is effective for in the de nition of FI. Clear mucus secretion must be treating levator ani syndrome and defecatory disorders. excluded by careful questioning. Flatus incontinence is oftenincludedinthedefinition of anal incontinence but not fi fi Keywords: Anorectal Disorders; Fecal Incontinence; Con- in the current diagnosis of FI because it is dif cult to de ne fl stipation; Dyssynergic Defecation; Levator Ani Syndrome; when isolated passage of atus is abnormal. FI is often Anorectal Pain; Biofeedback Therapy. multifactorial and occurs in conditions that cause diarrhea, impair colorectal storage capacity, and/or weaken the pelvic floor (Table 2). FI is considered abnormal after toilet training has been achieved, generally around 4 years norectal disorders are defined by specific symptoms of age.9 A and, in the case of functional disorders of defecation, also with abnormal diagnostic tests. Our understanding of these disorders continues to evolve with the availability of newer techniques to characterize anorectal structure and 1–3 function. Consequently, the distinction between “organic” Abbreviations used in this paper: ARM, anorectal manometry; CI, confi- and “functional” anorectal disorders may be difficult in dence interval; DRE, digital rectal examination; EMG, electromyography; 1–3 FDD, functional defecation disorder; FI, fecal incontinence; IBS, irritable individual patient. bowel syndrome; MRI, magnetic resonance imaging; OR, odds ratio. Anorectal disorders, such as fecal incontinence, are Most current article usually defined by specific symptoms, but functional disor- © 2016 by the AGA Institute ders of defecation require symptoms and anorectal physi- 0016-5085/$36.00 4 ological testing. While bowel symptoms recorded by http://dx.doi.org/10.1053/j.gastro.2016.02.009 May 2016 Functional Anorectal Disorders 1431 Table 1.Functional Anorectal Disorders Impact on quality of life and psychosocial factors. Persons with FI report that poor bowel control F. Functional anorectal disorders restricts their social life; other issues pertain to toilet F1. Fecal incontinence F2. Functional anorectal pain location, hygiene/odor issues, coping strategies, fear, F2a. Levator ani syndrome physical activities, embarrassment, and unpredictability of 27 F2b. Unspecifed functional anorectal pain bowel habits. Co-existent psychological problems may F2c. Proctalgia fugax include anxiety and depression,28,29 poor self-esteem, and F3. Functional defecation disorders problems with sexual relationships.30 Quality of life issues F3a. Dyssynergic defecation can be evaluated by generic or disease-specificin- F3b. Inadequate defecatory propulsion struments, such as the Rockwood Fecal Incontinence Quality of Life Scale, modified Manchester Health Ques- tionnaire, Fecal Incontinence and Constipation Assessment Quality of Life scale. FI symptoms can also be Epidemiology assessed by Pelvic Organ Prolapse/Incontinence Sexual Prevalence. Several large community-based stud- QuestionnaireÀIUGA (International Urogynecology – 31–34 ies10 17 have suggested that FI is common, with a preva- Association). There is a significant correlation be- 31,35 lence ranging from 7% to 15% in community-dwelling tween symptom severity and QOL in FI. FI was asso- women, 18% to 33% in hospitals, and 50% to 70% in ciated with increased mortality in some, but not all 36–38 nursing homes.18,19 The prevalence is either compara- studies. but whether it is due to FI per se or condi- ble16,20 or lower in men than women.21,22 Some11,13,17,23 but tions associated with FI (age and comorbidity) is 16 not all16,24 studies reported a lower prevalence in African- unknown. American than white women, but similar prevalence Etiology and risk factors for fecal incontinence. The across races in men.24 Interestingly, the majority of patients etiology of incontinence is often multifactorial. Therefore, it seen in clinical practice are women. is more appropriate to focus on associated conditions, Variations in the prevalence of FI among studies may especially when they precede the onset of FI, and on risk reflect differences in survey methods, screening questions, factors for FI. In community surveys, bowel disturbances, reference time frame10,16,25 (1 year or past month), and especially diarrhea and rectal urgency, and the burden of definition of incontinence. Two studies evaluated the chronic illness were more important and independent risk ANORECTAL incidence of FI.23,26 In a community study (65 years and factors for FI than obstetric-related pelvic floor injury (eg, 2,16,26,39–41 older), the incidence of FI at 4 years was 17%, with 6% forceps use, complicated episiotomy). In a having FI at least monthly.23 In a follow-up community community-based cohort of 176 randomly selected women study (50 years and older), the incidence of FI was with FI and 176 without FI, the independent risk factors for 7.0%.26 FI were diarrhea (odds ratio [OR] ¼ 53; 95% confidence interval [CI]: 6.1À471), cholecystectomy (OR ¼ 4.2l 95% CI: 1.2À15), current smokers (OR ¼ 4.7; 95% CI: 1.4À15), rectocele (OR ¼ 4.9; 95% CI: 1.3À19), stress urinary in- Table 2.Common Causes of Fecal Incontinence continence (OR ¼ 3.1; 95% CI: 1.4À6.5), and body mass 41 Anal sphincter weakness index (per unit, OR ¼ 1.1; 95% CI: 1.004À1.1). Smoking, Traumatic: obstetric, surgical (eg, hemorrhoidectomy, internal external sphincter atrophy, and obesity are also risk fac- sphincterotomy, fistulectomy) tors for FI.2,11,13,17,41 Other conditions associated with FI Nontraumatic: scleroderma, idiopathic internal sphincter include advanced age, disease burden (comorbidity count, degeneration diabetes), anal sphincter trauma (obstetrical injury, prior Neuropathy surgery), and decreased physical activity.11,16,17,42,43 Peripheral (eg, pudendal) or generalized (eg, diabetes mellitus) Pelvic floor disorders Several diseases that affect anorectal sensorimotor dys- Rectal prolapse, descending perineum syndrome functions and/or alter bowel habits are also associated
Load more

Recommended publications
  • The American Society of Colon and Rectal Surgeons' Clinical Practice
    CLINICAL PRACTICE GUIDELINES The American Society of Colon and Rectal Surgeons’ Clinical Practice Guideline for the Evaluation and Management of Constipation Ian M. Paquette, M.D. • Madhulika Varma, M.D. • Charles Ternent, M.D. Genevieve Melton-Meaux, M.D. • Janice F. Rafferty, M.D. • Daniel Feingold, M.D. Scott R. Steele, M.D. he American Society of Colon and Rectal Surgeons for functional constipation include at least 2 of the fol- is dedicated to assuring high-quality patient care lowing symptoms during ≥25% of defecations: straining, Tby advancing the science, prevention, and manage- lumpy or hard stools, sensation of incomplete evacuation, ment of disorders and diseases of the colon, rectum, and sensation of anorectal obstruction or blockage, relying on anus. The Clinical Practice Guidelines Committee is com- manual maneuvers to promote defecation, and having less posed of Society members who are chosen because they than 3 unassisted bowel movements per week.7,8 These cri- XXX have demonstrated expertise in the specialty of colon and teria include constipation related to the 3 common sub- rectal surgery. This committee was created to lead inter- types: colonic inertia or slow transit constipation, normal national efforts in defining quality care for conditions re- transit constipation, and pelvic floor or defecation dys- lated to the colon, rectum, and anus. This is accompanied function. However, in reality, many patients demonstrate by developing Clinical Practice Guidelines based on the symptoms attributable to more than 1 constipation sub- best available evidence. These guidelines are inclusive and type and to constipation-predominant IBS, as well. The not prescriptive.
    [Show full text]
  • Linaclotide: a Novel Therapy for Chronic Constipation and Constipation- Predominant Irritable Bowel Syndrome Brian E
    Linaclotide: A Novel Therapy for Chronic Constipation and Constipation- Predominant Irritable Bowel Syndrome Brian E. Lacy, PhD, MD, John M. Levenick, MD, and Michael D. Crowell, PhD, FACG Dr. Lacy is Section Chief of Gastroenter- Abstract: Chronic constipation and irritable bowel syndrome ology and Hepatology and Dr. Levenick (IBS) are functional gastrointestinal disorders that significantly is a Gastroenterology Fellow in the affect patients’ quality of life. Chronic constipation and IBS are Division of Gastroenterology and prevalent—12% of the US population meet the diagnostic crite- Hepatology at Dartmouth-Hitchcock Medical Center in Lebanon, New ria for IBS, and 15% meet the criteria for chronic constipation— Hampshire. Dr. Crowell is a Professor and these conditions negatively impact the healthcare system of Medicine in the Division of from an economic perspective. Despite attempts at dietary Gastroenterology and Hepatology at modification, exercise, or use of over-the-counter medications, Mayo Clinic in Scottsdale, Arizona. many patients have persistent symptoms. Alternative treatment options are limited. This article describes linaclotide (Linzess, Address correspondence to: Dr. Brian E. Lacy Ironwood Pharmaceuticals/Forest Pharmaceuticals), a new, first- Division of Gastroenterology and in-class medication for the treatment of chronic constipation Hepatology, Area 4C and constipation-predominant IBS. Dartmouth-Hitchcock Medical Center 1 Medical Center Drive Lebanon, NH 03756; Tel: 603-650-5215; Fax: 603-650-5225; onstipation is
    [Show full text]
  • Overlap in Patient with Functional Dyspepsia and Unspecified Functional Anorectal Pain
    Acta Interna The Journal of Internal Medicine Vol. 6 No. 2 December 2016 Website Journal : http://jurnal.ugm.ac.id/jain Overlap in Patient with Functional Dyspepsia and Unspecified Functional Anorectal Pain Suharjo Broto Cahyono,1 Putut Bayupurnama,2 Neneng Ratnasari,2 Siti Nurdjanah2 1Department of Internal Medicine, Charitas Hospital, Palembang 2Division of Gastroenterology and Hepatology, Department of Internal Medicine, Faculty of Medicine, Gadjah Mada University-Sardjito General Hospital, Yogyakarta ABSTRAK Gangguan gastrointestinal fungsional (GGIF) mewakili gangguan yang sering dijumpai dan perlu mendapatkan perhatian dalam bidang gastroenterologi. Gangguan ini menyebabkan kecemasan, distress dan morbiditas. Pasien dengan gangguan ini sering memperlihatkan manifestasi klinis secara tumpang tindih. Pasien dispepsia fungsional seringkali tumang tindih dengan gangguan gastrointestinal lain, termasuk nyeri anorektal fungsional. Keadaan tumpang tindih ini dapat menimbulkan keluhan yang makin berat, kualitas hidup yang lebih buruk dan skor somatisasi yang lebih tinggi, dan pasien mengalami kecemasan, depresi atau insomnia lebih sering dibandingkan pasien yang tanpa problem tumpah tindih. GGIF ditegakkan berdasarkan kriteria Rome III dan eksklusi penyakit organik. Pendekatan multimodalitas dibutuhkan dalam mengatasi pasien yang menderita gangguan gastrointestinal fungsional. Pada tinjaun kasus ini, dilaporkan seorang pasien laki laki menderita gangguan dispepsia fungsional dan nyeri anorektal fungsional tidak spesifik. Kata kunci : gangguan
    [Show full text]
  • Reoperative Techniques and Management in Hirschsprung Disease: a Narrative Review
    14 Review Article Reoperative techniques and management in Hirschsprung disease: a narrative review Farokh R. Demehri^, Belinda H. Dickie Department of Surgery, Boston Children’s Hospital, Boston, MA, USA Contributions: (I) Conception and design: All authors; (II) Administrative support: None; (III) Provision of study materials or patients: None; (IV) Collection and assembly of data: All authors; (V) Data analysis and interpretation: All authors; (VI) Manuscript writing: All authors; (VII) Final approval of manuscript: All authors Correspondence to: Farokh R. Demehri, MD. Department of Surgery, Boston Children’s Hospital, 300 Longwood Ave, Fegan 3, Boston, MA 02115, USA. Email: [email protected]. Abstract: The majority of children who undergo operative management for Hirschsprung disease have favorable results. A subset of patients, however, have long-term dysfunctional stooling, characterized by either frequent soiling or obstructive symptoms. The evaluation and management of a child with poor function after pull-through for Hirschsprung disease should be conducted by an experienced multidisciplinary team. A systematic workup is focused on detecting pathologic and anatomic causes of pull- through dysfunction. This includes an exam under anesthesia, pathologic confirmation including a repeat biopsy, and a contrast enema, with additional studies depending on the suspected etiology. Obstructive symptoms may be due to technique-specific types of mechanical obstruction, histopathologic obstruction, or dysmotility—each of which may benefit from reoperative surgery. The causes of soiling symptoms include loss of the dentate line and damage to the anal sphincter, which generally do not benefit from revision of the pull-through, and pseudo-incontinence, which may reveal underlying obstruction. A thorough understanding of the types of complications associated with various pull-through techniques aids in the evaluation of a child with postoperative dysfunction.
    [Show full text]
  • Tegaserod in the Treatment of Constipation-Predominant Functional Gastrointestinal Disorders
    DRUG PROFILE Tegaserod in the treatment of constipation-predominant functional gastrointestinal disorders Anurag Agrawal & Irritable bowel syndrome is a common condition for which, until recently, treatment Peter Whorwell† options have been limited. Tegaserod has selective serotonin subtype 4 receptor agonist †Author for correspondence activity and acts by increasing gastrointestinal motility, secretion and possibly reducing ERC Building, First Floor, Wythenshawe Hospital, visceral sensitivity. It has been developed to treat patients with irritable bowel syndrome Southmoor Road, who suffer from abdominal pain, constipation and bloating. Studies so far suggest that it is Manchester, M23 9LT, an effective treatment for these symptoms with an excellent safety profile. Its role in other UK Tel.: +44 161 291 5813 functional gastrointestinal disorders, such as functional dyspepsia, is still being assessed. Fax: +44 161 291 4184 This review describes the structure, pharmacokinetic and pharmacodynamic properties of tegaserod and its effect on gastrointestinal physiology, as well as its clinical utility. Irritable bowel syndrome (IBS) is the most com- drugs such as antidiarrheals, laxatives, antispas- mon condition dealt with by gastroenterolo- modics and antidepressants. Behavioral therapy gists, accounting for up to 30% of their practice is sometimes tried in patients who do not and 10% of primary care case loads [1]. It is respond to conventional treatment. characterized by abdominal pain or discomfort In addition to its costs to the patient, IBS also often related to a change in bowel habit and fre- has a significant direct and indirect economic quently exacerbated by eating. Investigation burden. The direct cost in terms of healthcare reveals no structural abnormality, although a utilization has been estimated to be between variety of gastrointestinal (GI) physiological US$1.7–10 billion/year in the USA alone.
    [Show full text]
  • Prevalence of Functional Disorders of the Bowel, Rectum, and Anus in a Tertiary Urogynecology Population
    200 Jelovsek J E1, Barber M D1, Walters M D1, Paraiso M F1 1. The Cleveland Clinic Foundation PREVALENCE OF FUNCTIONAL DISORDERS OF THE BOWEL, RECTUM, AND ANUS IN A TERTIARY UROGYNECOLOGY POPULATION Hypothesis / aims of study Straining is frequently mentioned as a possible etiologic factor in pelvic floor disorders and pelvic denervation. Constipation is a disease that results in frequent straining often seen in patients with pelvic floor disorders. The overall prevalence of constipation in the U.S. population is 14.7%, with 4.6% being functional constipation, 4.6% outlet subtype, 2.1% IBS- constipation subtype, and 3.4% IBS-outlet[1]. The prevalence and clinical subtypes of constipation and other functional bowel, rectal and anal disorders have not been well characterized in women with urinary incontinence (UI) and pelvic organ prolapse (POP). The specific aims of this study were: (1) to determine the prevalence of functional bowel disorders as defined by the Rome II criteria in a tertiary urogynecology clinic, (2) to determine the prevalence of subtypes of constipation, and (3) to determine whether demographic, clinical, or physical exam factors are associated with different types functional bowel, anal, and rectal disorders in patients with prolapse and incontinence. Study design, materials and methods This was a cross-sectional study design. One hundred and fifty consecutive female subjects presenting to a tertiary referral, urogynecology clinic were identified. Demographic, general medical, and physical exam information were collected. The prevalence of functional bowel disorders and functional disorders of the anus and rectum as defined by the Rome II criteria[2] were collected.
    [Show full text]
  • Constipation
    Constipation Constipation is defined as having a bowel movement fewer than three times per week. With constipation stools are usually hard, dry, Esophagus small in size, and difficult to eliminate. Some people who are constipated find it painful to Liver Stomach have a bowel movement and often experience straining, bloating, and the sensation of a full Pancreas bowel. Large Some people think they are constipated if they intestine do not have a bowel movement every day. However, normal stool elimination may be Small three times a day or three times a week, intestine depending on the person. Rectum Constipation is a symptom, not a disease. Anus Almost everyone experiences constipation at some point in their life, and a poor diet Appendix typically is the cause. Most constipation is temporary and not serious. Understanding its The digestive tract. causes, prevention, and treatment will help most people find relief. Self-treatment of constipation with overthe- counter (OTC) laxatives is by far the most Who gets constipated? common aid. Around $725 million is spent on Constipation is one of the most common laxative products each year in America. gastrointestinal complaints in the United States. More than 4 million Americans have frequent What causes constipation? constipation, accounting for 2.5 million To understand constipation, it helps to know physician visits a year. Those reporting how the colon, or large intestine, works. As food constipation most often are women and adults moves through the colon, the colon absorbs ages 65 and older. Pregnant women may have water from the food while it forms waste constipation, and it is a common problem products, or stool.
    [Show full text]
  • Anorectal Disorders
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE HHS Public Access provided by Carolina Digital Repository Author manuscript Author ManuscriptAuthor Manuscript Author Gastroenterology Manuscript Author . Author Manuscript Author manuscript; available in PMC 2017 September 25. Anorectal Disorders Satish S. C. Rao1, Adil E. Bharucha2, Giuseppe Chiarioni3,4, Richelle Felt-Bersma5, Charles Knowles6, Allison Malcolm7, and Arnold Wald8 1Division of Gastroenterology and Hepatology, Augusta University, Augusta, Georgia 2Department of Gastroenterology and Hepatology, Mayo College of Medicine, Rochester, Minnesota 3Division of Gastroenterology of the University of Verona, Azienda Ospedaliera Universitaria Integrata di Verona, Verona, Italy 4Division of Gastroenterology and Hepatology and UNC Center for Functional GI and Motility Disorders, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 5Department of Gastroenterology/Hepatology, VU Medical Center, Amsterdam, The Netherlands 6National Centre for Bowel Research and Surgical Innovation, Blizard Institute, Queen Mary University of London, London, United Kingdom 7Division of Gastroenterology, Royal North Shore Hospital, and University of Sydney, Sydney, Australia 8Division of Gastroenterology, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin Abstract This report defines criteria and reviews the epidemiology, pathophysiology, and management of the following common anorectal disorders: fecal incontinence (FI), functional anorectal pain, and functional defecation disorders. FI is defined as the recurrent uncontrolled passage of fecal material for at least 3 months. The clinical features of FI are useful for guiding diagnostic testing and therapy. Anorectal manometry and imaging are useful for evaluating anal and pelvic floor structure and function. Education, antidiarrheals, and biofeedback therapy are the mainstay of management; surgery may be useful in refractory cases.
    [Show full text]
  • The Significance of the Gut Microbiome in Children with Functional Constipation
    Reviews The significance of the gut microbiome in children with functional constipation Monika KwiatkowskaA–F, Aneta KrogulskaA–F Department of Pediatrics, Allergology and Gastroenterology, Ludwik Rydygier Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University in Toruń, Poland A – research concept and design; B – collection and/or assembly of data; C – data analysis and interpretation; D – writing the article; E – critical revision of the article; F – final approval of the article Advances in Clinical and Experimental Medicine, ISSN 1899–5276 (print), ISSN 2451–2680 (online) Adv Clin Exp Med. 2021;30(4):471–480 Address for correspondence Abstract Monika Kwiatkowska E-mail: [email protected] Constipation is a widespread problem in pediatric practice, affecting almost 30% of pediatric population. As much as 90–95% of constipation cases have a functional basis, and although the pathogenesis of func- Funding sources None declared tional constipation remains unclear, its etiology is considered to be multifactorial. Its growing prevalence has been attributed to the occurrence of disorders in the homeostasis of gastrointestinal microbiota. In humans, Conflict of interest the best known microbiome is that of the intestines, which has been the subject of a number of studies None declared based on recognition of the 16S rRNA gene sequence. Microbiota are believed to influence the pathogenesis of functional constipation by affecting peristalsis, relationship with diet, and physical activity. The paper evaluates the role of intestinal microbiota in functional constipation and describes its contribution to the onset Received on July 28, 2020 of disease. Determining the importance of the microbiome in the pathogenesis of functional constipation Reviewed on October 12, 2020 Accepted on December 6, 2020 creates hope for the development of new prevention and treatment methods.
    [Show full text]
  • Constipation in Adults Search Date October 2006 Frank Frizelle and Murray Barclay
    Dig . estive system disor Constipation in adults Search date October 2006 Frank Frizelle and Murray Barclay ABSTRACT INTRODUCTION: Although there are defined criteria for the diagnosis of constipation, in practice, diagnostic criteria are less rigid, and in part depend on the perception of normal bowel habit. Constipation is highly prevalent, with approximately 12 million general practitioner prescriptions for laxatives in England in 2001. METHODS AND OUTCOMES: We conducted a systematic review and aimed to answer the following clinical questions: What are the effects of non-drug interventions, and of other interventions, in adults with idiopathic chronic con- stipation? We searched: Medline, Embase, The Cochrane Library and other important databases up to October 2006 (BMJ Clinical evidence reviews are updated periodically, please check our website for the most up-to-date version of this review). We included harms alerts from relevant organisations such as the US Food and Drug Administration (FDA) and the UK Medicines and Healthcare products Regulatory Agency (MHRA). RESULTS: We found 42 systematic reviews, RCTs, or observational studies that met our inclusion criteria. We performed a GRADE evaluation of the quality of evidence for interventions. CONCLUSIONS: In this systematic review we present information relating to the effectiveness and safety of the following interventions: arachis oil, biofeedback, bisacodyl, cascara, docusate, exercise, glycerine suppositories, glycerol, high-fibre diet, increasing fluids, ispaghula husk, lactitol, lactulose, macrogols (polyethylene glycols), magnesium salts, methylcellulose, paraffin, phosphate enemas, seed oils, senna, sodium citrate enemas, sterculia. der QUESTIONS s What are the effects of non-drug interventions in adults with idiopathic chronic constipation?. 3 What are the effects of other treatments in adults with idiopathic chronic constipation?.
    [Show full text]
  • Systematic Literature Review and Indirect Treatment Comparison Of
    PGI8 Systematic literature review and indirect treatment comparison of linaclotide versus other oral constipation treatments in patients with chronic constipation H Okumura,1 W Tang,2 K Iwasaki,2 S Shoji,1 T Odaka,3 A Nakajima4 1Astellas Pharma Inc., Tokyo, Japan; 2Milliman Inc., Tokyo, Japan; 3Odaka Medical and Gastrointestinal Clinic, Chiba, Japan; 4Department of Gastroenterology and Hepatology, Yokohama City University Graduate School of Medicine, Yokohama, Japan INTRODUCTION Figure 2. Treatments included in NMA. Figure 3. Risk of bias of included trials. ● Chronic constipation (CC), including functional constipation, irritable bowel CC Naloxegol 12.5Naloxegol mg 5 mg IBS-C syndrome with constipation (IBS-C), and opioid-induced constipation (OIC), Naloxegol 25 mg OIC [12w] [4w] [12w] 1 Naloxegol[4w, 50 12w] mg [12w] [3w, 12w] CC and IBS-C negatively affects patients’ quality of life and has a prevalence rate of [3w, 12w]Alvimopan 0.5 mg [12w] Random sequence generation Alvimopan 1 mg Methylnaltrexone 450 mg 2,3 [4w] Methylnaltrexone 300 mg CC and OIC (selection bias) approximately 14% and 28% worldwide and in Japan, respectively. Methylnaltrexone 150 mg Lactitol[2w] 20 g Naloxone 2.5 mg Lactitol[7d] 10 g Allocation concealment ● The most commonly recommended treatments are polyethylene glycol [3w] Wheat (triticum) 20 g (selection bias) Naloxone 5 mg [4w] (PEG), lubiprostone, linaclotide, prucalopride, lactulose, bisacodyl, and [3w] Naloxone 10 mg Ispaghula 20 g 4 [4w] Blinding of participants and personnel [3w] Ispaghula 10.8 g dietary fibre ; in Japan, magnesium oxide followed by stimulant laxatives Naloxone 20 mg [14d] (performance bias) [3w] 5 Bisacodyl 10 mg are commonly used.
    [Show full text]
  • Female Chronic Pelvic Pain Syndromes 1 Standard of Care
    BRIGHAM AND WOMEN’S HOSPITAL Department of Rehabilitation Services Physical Therapy Standard of Care: Female Chronic Pelvic Pain Syndromes ICD 9 Codes: 719.45 Pain in the pelvic region 625.9 Vulvar/pelvic pain/vulvodynia/vestibulodynia (localized provoked vestibulodynia or unprovoked) 625.0 Dyspareunia 595.1 Interstitial cystitis/painful bladder syndrome 739.5 Pelvic floor dysfunction 569.42 Anal/rectal pain 564.6 Proctalgia fugax/spasm anal sphincter 724.79 Coccygodynia 781.3 Muscular incoordination (other possible pain diagnoses: prolapse 618.0) Case Type/Diagnosis: Chronic pelvic pain (CPP) can be defined as: “non-malignant pain perceived in structures related to the pelvis, in the anterior abdominal wall below the level of the umbilicus, the spine from T10 (ovarian nerve supply) or T12 (nerve supply to pelvic musculoskeletal structures) to S5, the perineum, and all external and internal tissues within these reference zones”. 1 Specifically, pelvic pain syndrome has been further defined as: “the occurrence of persistent or recurrent episodic pelvic pain associated with symptoms suggestive of lower urinary tract, sexual, bowel or gynecological dysfunction with no proven infection or other obvious pathology”.1 Generally, female pelvic pain has been defined as pain and dysfunction in and around the pelvic outlet, specifically the suprapubic, vulvar, and anal regions. A plethora of various terms/diagnoses encompass pelvic pain as a symptom, including but not limited to: chronic pelvic pain (CPP), vulvar pain, vulvodynia, vestibulitis/vestibulodynia (localized provoked vestibulodynia or unprovoked vestibulodynia), vaginismus, dyspareunia, interstitial cystitis (IC)/painful bladder syndrome (PBS), proctalgia fugax, levator ani syndrome, pelvic floor dysfunction, vulvodynia, vestibulitis/vestibulodynia dyspareunia, vaginismus, coccygodynia, levator ani syndrome, tension myaglia of the pelvic floor, shortened pelvic floor, and muscular incoordination of the pelvic floor muscles.
    [Show full text]